Skip to content
Research/Peptides/Melanotan II

Melanotan II

MT-II. Cyclic heptapeptide analog of α-MSH. Activates melanocortin receptors. Tanning, sexual function (in both sexes), appetite suppression. Research peptide.

Intelligence Profile

Safety Profile

Current evidence on Melanotan II safety is limited, with most data coming from case reports and small studies rather than comprehensive clinical trials.

Known Side Effects

Based on available case reports:

Oral and mucosal effects:

  • Changes in oral mucosa have been reported with Melanotan II injections
  • Potential risk factor for oral mucosal malignant melanoma, particularly with nasal spray formulations
  • The exact mechanism and frequency of these effects remain unclear

Other reported effects:

  • Nausea and flushing (commonly reported in user communities, though formal documentation is limited)
  • Darkening of skin and potentially mucous membranes
  • Potential effects on appetite and mood (suggested by animal studies)

Contraindications and High-Risk Populations

Evidence is insufficient to establish definitive contraindications. However, based on limited data, particular caution may be warranted for:

  • Individuals with history of melanoma or other skin cancers
  • Those with existing oral or mucosal lesions
  • Pregnant or breastfeeding women (no safety data available)

Drug Interactions

No formal drug interaction studies have been identified in the available literature. The compound's effects on melanocortin receptors could theoretically interact with medications affecting similar pathways, but specific interactions remain undocumented.

Regulatory Status and Quality Concerns

Melanotan II is not approved by major regulatory agencies (FDA, EMA) for human use. Products available through unregulated sources may have:

  • Unknown purity and concentration
  • Potential contamination
  • Inconsistent formulation

Evidence Limitations

The safety profile of Melanotan II is poorly characterized. Most available data consists of:

  • Individual case reports
  • Animal studies (limited applicability to humans)
  • One ongoing Phase 2 clinical trial for vitiligo treatment

Large-scale safety studies, dose-response relationships, and long-term safety data are notably absent from the current literature.


This information is for educational purposes only and does not constitute medical advice. Consult healthcare providers before considering any experimental compounds.

Free account required

Safety profile requires a free AXIFI account to access clinical data, safety profiles, and research papers.